

fees are required. Reconsideration and allowance of this application is respectfully requesting in view of the following amendments and remarks.

IN THE CLAIMS:

Please cancel claim 12 in its entirety, without prejudice.

Please amend claims 1 and 13-15 as follows:

1. (Amended) A method of treating a disease condition in a subject by vasodilation or vasorelaxation comprising:

selecting a subject;

administering a mixture of L-arginine and an inhibitor of Hmg-CoA reductase wherein said inhibitor of Hmg-CoA reductase is selected from the group consisting of:

lovastatin;

pravastatin;

simvastatin;

fluvastatin;

dalvastatin;

compactin;

HR-780;

BMV 22,089;

BMV 22,566;

SQ 33,600;

GR 95,030; or

CI 981;

obtaining periodic indicators of vasorelaxations for  
the subject; and

continuing administration of the mixture until a  
desirable state of [vasorelaxtion] vasorelaxation is obtained.

13. (Amended) The therapeutic mixture of claim [12,  
which] 15, wherein said substrate of NOS is a biological  
equivalent of L-arginine.

14. (Amended) The therapeutic mixture of claim 13,  
wherein said inhibitor of Hmg-CoA reductase is an agonist of NOS  
[is an inhibitor of Hmg-CoA reductase].

15. (Amended) A [The] therapeutic mixture comprised of  
[claim 14, wherein the agonist is] an inhibitor of Hmg-CoA  
reductase and a substrate of NOS, said inhibitor being selected  
from the group consisting of:

lovastatin;  
pravastatin;  
simvastatin;  
fluvastatin;  
dalvastatin;  
compactin;  
HR-780;

BMV 22,089;

BMV 22,566;

SQ 33,600;

GR 95,030; or

CI 981.

Please add the following new claim.

15<sup>13</sup> The therapeutic mixture of claim 13, wherein said inhibitor of Hmg-CoA reductase is pravastatin.

REMARKS

Applicant's attorney wishes to thank the Examiner for the careful consideration given this case as well as for the courteous interview extended to the undersigned on March 5, 1998. It is believed that all the issues raised in the Office Action were resolved in the interview.

Claims 12-14 were rejected under 35 U.S.C. § 102(b) as being anticipated by Morris et al. As a result of the agreements reached during the March 5 interview, claim 15 has been amended to be in independent form and to specifically recite the Hmg-CoA reductase inhibitors of claim 15. Claim 12 has been cancelled by this amendment and claims 13 and 14 now depend from new independent claim 15. As was agreed during the interview, it is now believed the rejection of claims 12-14 under 35 U.S.C. § 102(b) is made moot by this amendment. Accordingly, claims 13